Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Deferred Taxes (2017 - 2023)

Lineage Cell Therapeutics (LCTX) has 9 years of Deferred Taxes data on record, last reported at -$1.8 million in Q1 2023.

  • For Q1 2023, Deferred Taxes changed N/A year-over-year to -$1.8 million; the TTM value through Dec 2023 reached -$1.8 million, down 69.65%, while the annual FY2025 figure was -$5.3 million, N/A changed from the prior year.
  • Deferred Taxes reached -$1.8 million in Q1 2023 per LCTX's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $1.2 million in Q4 2022 and bottomed at -$4.4 million in Q1 2019.
  • Average Deferred Taxes over 5 years is -$1.1 million, with a median of -$1.0 million recorded in 2021.
  • Peak YoY movement for Deferred Taxes: skyrocketed 79.82% in 2020, then crashed 406.0% in 2021.
  • A 5-year view of Deferred Taxes shows it stood at -$991000.0 in 2019, then fell by 7.06% to -$1.1 million in 2020, then grew by 4.62% to -$1.0 million in 2021, then surged by 216.7% to $1.2 million in 2022, then crashed by 252.41% to -$1.8 million in 2023.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were -$1.8 million in Q1 2023, $1.2 million in Q4 2022, and -$1.0 million in Q3 2021.